Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesenCure for Pulmonary Manifestations in COVID-19
NCT04716998Phase 2Completed
- Sponsor
- Bonus BioGroup
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of MesenCure in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Bonus BioGroup. Primary endpoint: Safety of Mesencure at 30 days. Started Jan 2021; status: completed.
02
Drugs
MesenCure
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04716998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716998.